Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
Conditions
- RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Interventions
- DRUG: Belantamab mafodotin
Sponsor
PETHEMA Foundation
Collaborators